Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Scand J Gastroenterol

Retrieve available abstracts of 232 articles:
HTML format



Single Articles


    July 2021
  1. ATIA O, Gupta A, Travis S, Turner D, et al
    The pediatric ulcerative colitis activity index (PUCAI) predicts steroid-failure in adults with acute severe colitis.
    Scand J Gastroenterol. 2021 Jul 14:1-7. doi: 10.1080/00365521.2021.1947368.
    PubMed     Abstract available


    June 2021
  2. KOLEHMAINEN S, Ylisaukko-Oja T, Jokelainen J, Koivusalo M, et al
    Benefit of measuring vedolizumab concentrations in inflammatory bowel disease patients in a real-world setting.
    Scand J Gastroenterol. 2021 Jun 21:1-8. doi: 10.1080/00365521.2021.1938206.
    PubMed     Abstract available


  3. KRISTENSEN VA, Opheim R, Perminow G, Huppertz-Hauss G, et al
    Inflammatory bowel disease in South-Eastern Norway III (IBSEN III): a new population-based inception cohort study from South-Eastern Norway.
    Scand J Gastroenterol. 2021 Jun 21:1-7. doi: 10.1080/00365521.2021.1922746.
    PubMed     Abstract available


    May 2021
  4. LOPEZ-SERRANO A, Suarez MJ, Beso P, Algarra A, et al
    Virtual chromoendoscopy with iSCAN as an alternative method to dye-spray chromoendoscopy for dysplasia detection in long-standing colonic inflammatory bowel disease: a case-control study.
    Scand J Gastroenterol. 2021 May 27:1-9. doi: 10.1080/00365521.2021.1925339.
    PubMed     Abstract available


  5. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
    Physical exercise is associated with beneficial bone mineral density and body composition in young adults with childhood-onset inflammatory bowel disease.
    Scand J Gastroenterol. 2021 May 4:1-9. doi: 10.1080/00365521.2021.1913759.
    PubMed     Abstract available


    April 2021
  6. RUBIN DE CELIX C, Chaparro M, Moreno JA, Santander C, et al
    Colorectal cancer surveillance with chromoendoscopy in inflammatory bowel disease: results from a real-life experience.
    Scand J Gastroenterol. 2021 Apr 27:1-6. doi: 10.1080/00365521.2021.1918758.
    PubMed     Abstract available


  7. VAN DER GIESSEN J, Fuhler GM, van der Woude CJ
    A first pregnancy seems associated with a positive effect on the course of inflammatory bowel disease: data from a prospective pregnancy cohort.
    Scand J Gastroenterol. 2021 Apr 20:1-6. doi: 10.1080/00365521.2021.1910996.
    PubMed     Abstract available


  8. RANKALA R, Mattila K, Voutilainen M, Mustonen A, et al
    Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism.
    Scand J Gastroenterol. 2021 Apr 7:1-6. doi: 10.1080/00365521.2021.1908416.
    PubMed     Abstract available


    March 2021
  9. MOUM KM, Moum B, Opheim R
    Patients with inflammatory bowel disease on immunosuppressive drugs: perspectives' on COVID-19 and health care service during the pandemic.
    Scand J Gastroenterol. 2021 Mar 26:1-7. doi: 10.1080/00365521.2021.1901308.
    PubMed     Abstract available


  10. BEKIC D, Belosic Halle Z
    Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations.
    Scand J Gastroenterol. 2021 Mar 25:1-5. doi: 10.1080/00365521.2021.1902561.
    PubMed     Abstract available


  11. QVIST N, Vadstrup K, Alulis S, Borsi A, et al
    Increased use of biologics in the era of TNF-alpha inhibitors did not reduce surgical rate but prolonged the time from diagnosis to first time intestinal resection among patients with Crohn's disease and ulcerative colitis - a Danish register-based st
    Scand J Gastroenterol. 2021 Mar 18:1-8. doi: 10.1080/00365521.2021.1897670.
    PubMed     Abstract available


  12. BONNAUD G, Haennig A, Altwegg R, Caron B, et al
    Real-life pilot study on the impact of the telemedicine platform EasyMICI-MaMICI((R)) on quality of life and quality of care in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2021 Mar 10:1-7. doi: 10.1080/00365521.2021.1894602.
    PubMed     Abstract available


    February 2021
  13. ANKERSEN DV, Weimers P, Marker D, Teglgaard Peters-Lehm C, et al
    Costs of electronic health vs. standard care management of inflammatory bowel disease across three years of follow-up-a Danish register-based study.
    Scand J Gastroenterol. 2021 Feb 28:1-10. doi: 10.1080/00365521.2021.1892176.
    PubMed     Abstract available


  14. RONNBLOM A, Karlbom U
    Treatment and outcome of ulcerative colitis during the first 10 years after diagnosis in a prospectively followed population-based cohort.
    Scand J Gastroenterol. 2021 Feb 12:1-7. doi: 10.1080/00365521.2021.1882553.
    PubMed     Abstract available


    January 2021
  15. ERONEN H, Ilus T, Jussila A, Huhtala H, et al
    Long-term outcome of patients with acute ulcerative colitis after first course of intravenous corticosteroids.
    Scand J Gastroenterol. 2021 Jan 26:1-8. doi: 10.1080/00365521.2020.1867892.
    PubMed     Abstract available


    December 2020
  16. DORE MP, Fanciulli G, Manca A, Cocco V, et al
    Clinically relevant thyroid disorders and inflammatory bowel disease are inversely related: a retrospective case-control study.
    Scand J Gastroenterol. 2020 Dec 16:1-6. doi: 10.1080/00365521.2020.1861323.
    PubMed     Abstract available


  17. XI W, Li Z, Ren R, Sai XY, et al
    Effect of antibiotic therapy in patients with ulcerative colitis: a meta-analysis of randomized controlled trials.
    Scand J Gastroenterol. 2020 Dec 12:1-9. doi: 10.1080/00365521.2020.1858958.
    PubMed     Abstract available


  18. DE JONG ME, Taal E, Thomas PWA, Romkens TEH, et al
    Cross-cultural translation and validation of the IBD-control questionnaire in The Netherlands: a patient-reported outcome measure in inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Dec 10:1-7. doi: 10.1080/00365521.2020.1857430.
    PubMed     Abstract available


  19. STRIK AS, Lowenberg M, Mould DR, Berends SE, et al
    Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial.
    Scand J Gastroenterol. 2020 Dec 8:1-10. doi: 10.1080/00365521.2020.1856405.
    PubMed     Abstract available


  20. OSTLUND I, Werner M, Karling P
    Self-monitoring with home based fecal calprotectin is associated with increased medical treatment. A randomized controlled trial on patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Dec 7:1-8. doi: 10.1080/00365521.2020.1854342.
    PubMed     Abstract available


  21. KRISTJANSSON VB, Lund SH, Grondal G, Sveinsdottir SV, et al
    Increased risk of inflammatory bowel disease among patients treated with rituximab in Iceland from 2001 to 2018.
    Scand J Gastroenterol. 2020 Dec 5:1-7. doi: 10.1080/00365521.2020.1854847.
    PubMed     Abstract available


    November 2020
  22. LAMERS CR, de Roos NM, Bongers CCWG, Ten Haaf DSM, et al
    Repeated prolonged moderate-intensity walking exercise does not appear to have harmful effects on inflammatory markers in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Nov 19:1-8. doi: 10.1080/00365521.2020.1845791.
    PubMed     Abstract available


  23. KRISHNAPRASAD K, Walsh A, Begun J, Bell S, et al
    Crohn's Colitis Care (CCCare): bespoke cloud-based clinical management software for inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Nov 8:1-8. doi: 10.1080/00365521.2020.1839960.
    PubMed     Abstract available


  24. WALENTYNOWICZ M, Van de Pavert I, Coenen S, Fierens L, et al
    Worries and concerns of inflammatory bowel disease (IBD) patients in Belgium - a validation of the Dutch rating form.
    Scand J Gastroenterol. 2020 Nov 1:1-6. doi: 10.1080/00365521.2020.1839962.
    PubMed     Abstract available


    October 2020
  25. ANKERSEN DV, Weimers P, Marker D, Johannesen T, et al
    eHealth: Disease activity measures are related to the faecal gut microbiota in adult patients with ulcerative colitis.
    Scand J Gastroenterol. 2020 Oct 12:1-10. doi: 10.1080/00365521.2020.1829031.
    PubMed     Abstract available


    September 2020
  26. PETTERSSON N, Kragsbjerg F, Hamrin A, Bergman S, et al
    Increased chronic pain in patients with ulcerative colitis is mostly associated to increased disease activity. A cross-sectional case-control study.
    Scand J Gastroenterol. 2020 Sep 18:1-7. doi: 10.1080/00365521.2020.1820567.
    PubMed     Abstract available


    August 2020
  27. LO B, Vind I, Vester-Andersen MK, Burisch J, et al
    Validation of ulcerative colitis and Crohn's disease and their phenotypes in the Danish National Patient Registry using a population-based cohort.
    Scand J Gastroenterol. 2020 Aug 24:1-5. doi: 10.1080/00365521.2020.1807598.
    PubMed     Abstract available


  28. VIOLA A, Fontana A, Belvedere A, Scoglio R, et al
    Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach.
    Scand J Gastroenterol. 2020 Aug 24:1-9. doi: 10.1080/00365521.2020.1807599.
    PubMed     Abstract available


  29. SILVA JC, Fernandes C, Rodrigues J, Fernandes S, et al
    Endoscopic and histologic activity assessment considering disease extent and prediction of treatment failure in ulcerative colitis.
    Scand J Gastroenterol. 2020 Aug 8:1-6. doi: 10.1080/00365521.2020.1803397.
    PubMed     Abstract available


  30. MALICKOVA K, Kratka Z, Luxova S, Bortlik M, et al
    Anti-SARS-CoV-2 antibody testing in IBD healthcare professionals: are we currently able to provide COVID-free IBD clinics?
    Scand J Gastroenterol. 2020;55:917-919.
    PubMed     Abstract available


    July 2020
  31. ARIEIRA C, Dias de Castro F, Curdia Goncalves T, Moreira MJ, et al
    Combination therapy in inflammatory bowel disease patients: do we need to maximize the dose of azathioprine?
    Scand J Gastroenterol. 2020 Jul 20:1-4. doi: 10.1080/00365521.2020.1792543.
    PubMed     Abstract available


  32. KARJALAINEN EK, Renkonen-Sinisalo L, Lepisto AH
    Dysplasia in the mucosal biopsy specimen is still a warning sign of cancer in ulcerative colitis.
    Scand J Gastroenterol. 2020 Jul 16:1-5. doi: 10.1080/00365521.2020.1794024.
    PubMed     Abstract available


  33. WHITE JR, Din S, Ingram RJM, Foley S, et al
    Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK - a retrospective observational study.
    Scand J Gastroenterol. 2020 Jul 11:1-10. doi: 10.1080/00365521.2020.1790647.
    PubMed     Abstract available


  34. ALEKNONYTE-RESCH M, Freitag-Wolf S, Schreiber S, Krawczak M, et al
    Case-only analysis of gene-gene interactions in inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jul 10:1-10. doi: 10.1080/00365521.2020.1790646.
    PubMed     Abstract available


  35. VAN DER SLOOT KWJ, Voskuil MD, Visschedijk MC, Festen EAM, et al
    Latent cytomegalovirus infection does not influence long-term disease outcomes in inflammatory bowel disease, but is associated with later onset of disease.
    Scand J Gastroenterol. 2020 Jul 7:1-6. doi: 10.1080/00365521.2020.1786853.
    PubMed     Abstract available


  36. BUHL S, Dorn-Rasmussen M, Brynskov J, Ainsworth MA, et al
    Therapeutic thresholds and mechanisms for primary non-response to infliximab in inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jul 6:1-7. doi: 10.1080/00365521.2020.1786852.
    PubMed     Abstract available


    June 2020
  37. SENGUPTA NK, Azizov A, Halder S, Xenodemetropoulos T, et al
    Higher vedolizumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jun 23:1-6. doi: 10.1080/00365521.2020.1780470.
    PubMed     Abstract available


  38. XU Y, Xu F, Li W, Li M, et al
    The diagnostic role and clinical association of serum proteinase 3 anti-neutrophil cytoplasmic antibodies in Chinese patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jun 22:1-8. doi: 10.1080/00365521.2020.1781926.
    PubMed     Abstract available


  39. MAGDZIAK A, Szlak J, Mroz A, Wieszczy P, et al
    A stool test in patients with active ulcerative colitis helps exclude cytomegalovirus disease.
    Scand J Gastroenterol. 2020 Jun 19:1-7. doi: 10.1080/00365521.2020.1771760.
    PubMed     Abstract available


  40. JUDGE C, McGettigan N, Ryan T, Hazel K, et al
    Irish data on the safety and efficacy of vedolizumab in the treatment of inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Jun 16:1-9. doi: 10.1080/00365521.2020.1779340.
    PubMed     Abstract available


  41. WEN Y, Niu J, Zhang F, Wu J, et al
    Heat shock transcription factor 2 predicts mucosal healing and promotes mucosal repair of ulcerative colitis.
    Scand J Gastroenterol. 2020 Jun 13:1-10. doi: 10.1080/00365521.2020.1774924.
    PubMed     Abstract available


  42. FRIMOR C, Kjeldsen J, Ainsworth M
    Treatment to target in patients with inflammatory bowel disease. What is the evidence?
    Scand J Gastroenterol. 2020 Jun 5:1-9. doi: 10.1080/00365521.2020.1764091.
    PubMed     Abstract available


    May 2020
  43. ROSA I, Silva P, da Mata S, Magro F, et al
    Methylation patterns in dysplasia in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2020 May 26:1-10. doi: 10.1080/00365521.2020.1766552.
    PubMed     Abstract available


  44. RASMUSSEN B, Haastrup P, Wehberg S, Kjeldsen J, et al
    Predictors of health-related quality of life in patients with moderate to severely active ulcerative colitis receiving biological therapy.
    Scand J Gastroenterol. 2020 May 22:1-8. doi: 10.1080/00365521.2020.1768282.
    PubMed     Abstract available


  45. KOTANI S, Fukuba N, Kawashima K, Mishima Y, et al
    Prevalence of functional dyspepsia-like symptoms in ulcerative colitis patients in clinical remission and overlap with irritable bowel syndrome-like symptoms.
    Scand J Gastroenterol. 2020 May 15:1-5. doi: 10.1080/00365521.2020.1761998.
    PubMed     Abstract available


    April 2020
  46. RONNBLOM A, Karlbom U
    Acute severe attacks of ulcerative colitis in a population-based cohort: epidemiology, treatment and outcome.
    Scand J Gastroenterol. 2020 Apr 27:1-5. doi: 10.1080/00365521.2020.1757143.
    PubMed     Abstract available


  47. ZHANG CC, Voitl R, Hippchen T, Weiss KH, et al
    Evaluation of two functional CD24 polymorphisms in primary sclerosing cholangitis.
    Scand J Gastroenterol. 2020 Apr 24:1-7. doi: 10.1080/00365521.2020.1755357.
    PubMed     Abstract available


  48. VON VOLKMANN HL, Bronstad I, Tronstad RR, Dizdar V, et al
    Plasma levels of guanylins are reduced in patients with Crohn's disease.
    Scand J Gastroenterol. 2020 Apr 20:1-5. doi: 10.1080/00365521.2020.1748224.
    PubMed     Abstract available


  49. SHRESTHA S, Olen O, Eriksson C, Everhov AH, et al
    The use of ICD codes to identify IBD subtypes and phenotypes of the Montreal classification in the Swedish National Patient Register.
    Scand J Gastroenterol. 2020;55:430-435.
    PubMed     Abstract available


  50. ZHAO L, Tang Y, Lei N, Zhou D, et al
    Clinical features and monocyte/macrophage subsets characterization in granulomatous vs non-granulomatous Crohn's disease.
    Scand J Gastroenterol. 2020;55:442-448.
    PubMed     Abstract available


  51. KRISTENSEN VA, Cvancarova M, Hoivik ML, Moum B, et al
    Serological antibodies and surgery in a population-based inception cohort of Crohn's disease patients - the IBSEN study.
    Scand J Gastroenterol. 2020;55:436-441.
    PubMed     Abstract available


  52. FREITAS M, Arieira C, Carvalho PB, Rosa B, et al
    Simplify to improve in capsule endoscopy - TOP 100 is a swift and reliable evaluation tool for the small bowel inflammatory activity in Crohn's disease.
    Scand J Gastroenterol. 2020;55:408-413.
    PubMed     Abstract available


    March 2020
  53. SOLBERG F, Ohlsson B
    Microscopic colitis and its associations with complications observed in classic inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2020 Mar 17:1-9. doi: 10.1080/00365521.2020.1739325.
    PubMed     Abstract available


  54. SOBOLEWSKA-WLODARCZYK A, Wlodarczyk M, Zielinska A, Siwinski P, et al
    Circadian rhythm abnormalities in patients with inflammatory bowel disease - association with adipokine profile.
    Scand J Gastroenterol. 2020 Mar 17:1-7. doi: 10.1080/00365521.2020.1737727.
    PubMed     Abstract available


  55. ZOU Y, Wu L, Xu W, Zhou X, et al
    Correlation between antibiotic use in childhood and subsequent inflammatory bowel disease: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2020 Mar 17:1-11. doi: 10.1080/00365521.2020.1737882.
    PubMed     Abstract available


  56. COENEN S, Nijns E, Weyts E, Geens P, et al
    Development and feasibility of a telemonitoring tool with full integration in the electronic medical record: a proof of concept study for patients with inflammatory bowel disease in remission on biological therapy.
    Scand J Gastroenterol. 2020 Mar 17:1-7. doi: 10.1080/00365521.2020.1735506.
    PubMed     Abstract available


  57. MAK JWY, So J, Tang W, Yip TCF, et al
    Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
    Scand J Gastroenterol. 2020 Mar 2:1-8. doi: 10.1080/00365521.2020.1731760.
    PubMed     Abstract available


  58. ALULIS S, Vadstrup K, Borsi A, Nielsen A, et al
    Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015.
    Scand J Gastroenterol. 2020 Mar 2:1-7. doi: 10.1080/00365521.2020.1726445.
    PubMed     Abstract available


    February 2020
  59. GARSHOL BF, Aamodt G, Madsen C, Vatn MH, et al
    The effect of nitrogen dioxide on low birth weight in women with inflammatory bowel disease: a Norwegian pregnancy cohort study (MoBa).
    Scand J Gastroenterol. 2020 Feb 17:1-7. doi: 10.1080/00365521.2020.1726446.
    PubMed     Abstract available


  60. HOSSAIN A, Lordal M, Olsson AE, Storlahls A, et al
    Sustained clinical benefit, improved quality of life, and reduced intestinal surgery from maintenance infliximab treatment in inflammatory bowel disease().
    Scand J Gastroenterol. 2020 Feb 13:1-6. doi: 10.1080/00365521.2020.1722738.
    PubMed     Abstract available


  61. SIGURDSSON GV, Schmidt S, Mellstrom D, Ohlsson C, et al
    Altered body composition profiles in young adults with childhood-onset inflammatory bowel disease.
    Scand J Gastroenterol. 2020 Feb 1:1-9. doi: 10.1080/00365521.2020.1716061.
    PubMed     Abstract available


  62. DAVIES M, Dodd S, Coultate M, Ross A, et al
    From Paris to Montreal: disease regression is common during long term follow-up of paediatric Crohn's disease.
    Scand J Gastroenterol. 2020;55:148-153.
    PubMed     Abstract available


    January 2020
  63. KIM ES, Lee HS, Kim SK, Kim EY, et al
    Fecal calprotectin is more accurate than fecal immunochemical test for predicting mucosal healing in quiescent ulcerative colitis: a prospective multicenter study.
    Scand J Gastroenterol. 2020 Jan 26:1-6. doi: 10.1080/00365521.2020.1714716.
    PubMed     Abstract available


  64. ANGELISON L, Almer S, Davidsdottir L, Hammarlund P, et al
    Short and long-term efficacy of adalimumab in ulcerative colitis: a real-life study.
    Scand J Gastroenterol. 2020 Jan 21:1-9. doi: 10.1080/00365521.2020.1713210.
    PubMed     Abstract available


  65. VADSTRUP K, Alulis S, Borsi A, Elkjaer Stallknecht S, et al
    Societal costs attributable to Crohn's disease and ulcerative colitis within the first 5 years after diagnosis: a Danish nationwide cost-of-illness study 2002-2016.
    Scand J Gastroenterol. 2020 Jan 21:1-6. doi: 10.1080/00365521.2019.1707276.
    PubMed     Abstract available


  66. AMOUZADEH-GHADIKOLAI O, Reicht G, Quehenberger F, Robier C, et al
    Basophilia of the peripheral blood in patients with ulcerative colitis.
    Scand J Gastroenterol. 2020 Jan 12:1-3. doi: 10.1080/00365521.2019.1710247.
    PubMed     Abstract available


  67. ARKTEG CB, Goll R, Gundersen MD, Anderssen E, et al
    Mucosal gene transcription of ulcerative colitis in endoscopic remission.
    Scand J Gastroenterol. 2020 Jan 9:1-9. doi: 10.1080/00365521.2019.1710245.
    PubMed     Abstract available


  68. MOLANDER P, Kemppainen H, Ilus T, Sipponen T, et al
    Long-term deep remission during maintenance therapy with biological agents in inflammatory bowel diseases.
    Scand J Gastroenterol. 2020;55:34-40.
    PubMed     Abstract available


    December 2019
  69. PIGNICZKI D, Rutka M, Farkas K, Molnar T, et al
    Lupus-like reactions in patients with inflammatory bowel disease: a little bit different data from another center.
    Scand J Gastroenterol. 2019 Dec 9:1. doi: 10.1080/00365521.2019.1690038.
    PubMed    


  70. RYHLANDER J, Ringstrom G, Simren M, Stotzer PO, et al
    Undergoing repeated colonoscopies - experiences from patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Dec 9:1-6. doi: 10.1080/00365521.2019.1698649.
    PubMed     Abstract available


    November 2019
  71. YILMAZ KARADAG F, Arslan F, Caskurlu H, Cag Y, et al
    Efficacy of antiviral treatment in cytomegalovirus detected ulcerative colitis: meta-analysis of available data.
    Scand J Gastroenterol. 2019 Nov 13:1-7. doi: 10.1080/00365521.2019.1688860.
    PubMed     Abstract available


    October 2019
  72. SEGERMAN F, Clarkson S, Sjoberg K
    Marked regional variations in the prevalence of inflammatory bowel disease in a limited geographical region are not associated with compounds in the drinking water.
    Scand J Gastroenterol. 2019 Oct 15:1-11. doi: 10.1080/00365521.2019.1674374.
    PubMed     Abstract available


  73. AMCOFF K, Cao Y, Zhulina Y, Lampinen M, et al
    Prognostic significance of faecal eosinophil granule proteins in inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Oct 2:1-8. doi: 10.1080/00365521.2019.1670251.
    PubMed     Abstract available


    September 2019
  74. BODINI G, Demarzo MG, Saracco M, Coppo C, et al
    High anti-TNF alfa drugs trough levels are not associated with the occurrence of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Sep 25:1-6. doi: 10.1080/00365521.2019.1666914.
    PubMed     Abstract available


  75. RIBALDONE DG, Vernero M, Parisi S, Ditto MC, et al
    Risk factors of suspected spondyloarthritis among inflammatory bowel disease patients.
    Scand J Gastroenterol. 2019 Sep 24:1-4. doi: 10.1080/00365521.2019.1668052.
    PubMed     Abstract available


  76. MALHAM M, Carlsen K, Riis L, Paerregaard A, et al
    Plasma calprotectin is superior to serum calprotectin as a biomarker of intestinal inflammation in ulcerative Colitis.
    Scand J Gastroenterol. 2019 Sep 17:1-6. doi: 10.1080/00365521.2019.1665097.
    PubMed     Abstract available


  77. LUDVIGSSON JF, Andersson M, Bengtsson J, Eberhardson M, et al
    Swedish Inflammatory Bowel Disease Register (SWIBREG) - a nationwide quality register.
    Scand J Gastroenterol. 2019 Sep 9:1-13. doi: 10.1080/00365521.2019.1660799.
    PubMed     Abstract available


  78. MACALUSO FS, Sapienza C, Ventimiglia M, Renna S, et al
    Lupus-like reactions in patients with inflammatory bowel disease treated with anti-TNFs are insidious adverse events: data from a large single-center cohort.
    Scand J Gastroenterol. 2019 Sep 6:1-5. doi: 10.1080/00365521.2019.1663260.
    PubMed     Abstract available


    August 2019
  79. TENCA A, Jaakkola T, Farkkila M, Arola J, et al
    Impact of paediatric onset primary sclerosing cholangitis on clinical course and outcome of inflammatory bowel disease: a case-control population-based study in Finland.
    Scand J Gastroenterol. 2019 Aug 10:1-7. doi: 10.1080/00365521.2019.1648547.
    PubMed     Abstract available


    July 2019
  80. OH SJ, Lee CK, Kim YW, Jeong SJ, et al
    True cytomegalovirus colitis is a poor prognostic indicator in patients with ulcerative colitis flares: the 10-year experience of an academic referral inflammatory bowel disease center.
    Scand J Gastroenterol. 2019 Jul 29:1-8. doi: 10.1080/00365521.2019.1646798.
    PubMed     Abstract available


  81. MALHAM M, Lilje B, Houen G, Winther K, et al
    The microbiome reflects diagnosis and predicts disease severity in paediatric onset inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Jul 22:1-7. doi: 10.1080/00365521.2019.1644368.
    PubMed     Abstract available


  82. CARMONA-ABELLAN M, Rodriguez-Lago I, Cabriada JL, Gomez-Esteban JC, et al
    The relationship between inflammatory bowel disease and Parkinson's disease: true or fiction?
    Scand J Gastroenterol. 2019 Jul 17:1-4. doi: 10.1080/00365521.2019.1641739.
    PubMed     Abstract available


  83. MENDALL M, Jensen CB, Angquist LH, Baker JL, et al
    Childhood growth and risk of inflammatory bowel disease: a population-based study of 317,030 children.
    Scand J Gastroenterol. 2019 Jul 11:1-6. doi: 10.1080/00365521.2019.1635201.
    PubMed     Abstract available


  84. MOLANDER P, Ylanne K
    Impact of ulcerative colitis on patients' lives: results of the Finnish extension of a global ulcerative colitis narrative survey.
    Scand J Gastroenterol. 2019 Jul 7:1-7. doi: 10.1080/00365521.2019.1635637.
    PubMed     Abstract available


  85. PUOLANNE AM, Kolho KL, Alfthan H, Farkkila M, et al
    Is home monitoring of inflammatory bowel disease feasible? A randomized controlled study.
    Scand J Gastroenterol. 2019 Jul 2:1-6. doi: 10.1080/00365521.2019.1618910.
    PubMed     Abstract available


    June 2019
  86. YLISAUKKO-OJA T, Torvinen S, Ventola H, Schmidt S, et al
    Healthcare resource utilization and treatment costs of Finnish chronic inflammatory bowel disease patients treated with infliximab().
    Scand J Gastroenterol. 2019 Jun 16:1-7. doi: 10.1080/00365521.2019.1627579.
    PubMed     Abstract available


  87. VAN ASSELDONK DP, Simsek M, de Boer NKH, Jharap B, et al
    Limited relevance and progression of histological alterations in the liver during thioguanine therapy in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2019 Jun 16:1-8. doi: 10.1080/00365521.2019.1629006.
    PubMed     Abstract available


    May 2019
  88. NARULA N, Lauzon B, Marshall JK
    Higher adalimumab serum levels do not increase the risk of adverse events in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 30:1-6. doi: 10.1080/00365521.2019.1621367.
    PubMed     Abstract available


  89. KOLEHMAINEN S, Lepisto A, Farkkila M
    Impact of anti-TNF-alpha therapy on colectomy rate and indications for colectomy in ulcerative colitis: comparison of two patient cohorts from 2005 to 2007 and from 2014 to 2016().
    Scand J Gastroenterol. 2019 May 28:1-5. doi: 10.1080/00365521.2019.1620326.
    PubMed     Abstract available


  90. BERENDS SE, Strik AS, Jansen JM, de Boer NK, et al
    Pharmacokinetics of golimumab in moderate to severe ulcerative colitis: the GO-KINETIC study.
    Scand J Gastroenterol. 2019 May 27:1-7. doi: 10.1080/00365521.2019.1619828.
    PubMed     Abstract available


  91. COENEN S, Weyts E, Geens P, Vermeire S, et al
    Short Health Scale: a valid and reliable measure of quality of life in Dutch speaking patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 18:1-5. doi: 10.1080/00365521.2019.1616214.
    PubMed     Abstract available


  92. LIU Y, Liu X
    Research progress of P2X7 receptor in inflammatory bowel disease.
    Scand J Gastroenterol. 2019 May 6:1-7. doi: 10.1080/00365521.2019.1609077.
    PubMed     Abstract available


  93. CHEN HX, Yuan ZY, Wu KX, Liu C, et al
    The study of methylation and single nucleotide polymorphisms of cancer-related genes in patients with early-stage ulcerative colitis.
    Scand J Gastroenterol. 2019 May 2:1-5. doi: 10.1080/00365521.2019.1594355.
    PubMed     Abstract available


    April 2019
  94. DILILLO D, Zuccotti GV, Galli E, Meneghin F, et al
    Noninvasive testing in the management of children with suspected inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Apr 28:1-6. doi: 10.1080/00365521.2019.1604799.
    PubMed     Abstract available


  95. SARAIVA S, Cortez-Pinto J, Barosa R, Castela J, et al
    Evaluation of fatigue in inflammatory bowel disease - a useful tool in daily practice.
    Scand J Gastroenterol. 2019 Apr 23:1-6. doi: 10.1080/00365521.2019.1602669.
    PubMed     Abstract available


  96. RODRIGUEZ-LAGO I, Sempere L, Gutierrez A, Nunez A, et al
    Granulocyte-monocyte apheresis: an alternative combination therapy after loss of response to anti-TNF agents in ulcerative colitis.
    Scand J Gastroenterol. 2019 Apr 14:1-6. doi: 10.1080/00365521.2019.1600715.
    PubMed     Abstract available


  97. COLD F, Browne PD, Gunther S, Halkjaer SI, et al
    Multidonor FMT capsules improve symptoms and decrease fecal calprotectin in ulcerative colitis patients while treated - an open-label pilot study.
    Scand J Gastroenterol. 2019 Apr 4:1-8. doi: 10.1080/00365521.2019.1585939.
    PubMed     Abstract available


  98. RIBALDONE DG, Pellicano R, Vernero M, Caviglia GP, et al
    Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis.
    Scand J Gastroenterol. 2019 Apr 4:1-7. doi: 10.1080/00365521.2019.1597159.
    PubMed     Abstract available


    March 2019
  99. NIELSEN HM, Dalager-Pedersen M, Nielsen H
    Risk of inflammatory bowel disease after Campylobacter jejuni and Campylobacter concisus infection: a population-based cohort study.
    Scand J Gastroenterol. 2019 Mar 24:1-8. doi: 10.1080/00365521.2019.1578406.
    PubMed     Abstract available


  100. SAFAEIAN R, Howarth GS, Lawrance IC, Trinder D, et al
    Emu Oil reduces disease severity in a mouse model of chronic ulcerative colitis.
    Scand J Gastroenterol. 2019 Mar 23:1-8. doi: 10.1080/00365521.2019.1581253.
    PubMed     Abstract available


  101. BOTS SJ, Kuin S, Ponsioen CY, Gecse KB, et al
    Relapse rates and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy.
    Scand J Gastroenterol. 2019;54:281-288.
    PubMed     Abstract available


    February 2019
  102. VENTURIERI MO, Komati JTS, Lopes LHC, Sdepanian VL, et al
    Treatment with Noripurum EV((R)) is effective and safe in pediatric patients with inflammatory bowel disease and iron deficiency anemia.
    Scand J Gastroenterol. 2019 Feb 20:1-7. doi: 10.1080/00365521.2019.1570326.
    PubMed     Abstract available


  103. DIGNASS AU, Siegmund B, Goertz R, Schneidewind G, et al
    Indirect comparison of vedolizumab and adalimumab for biologic-naive patients with ulcerative colitis.
    Scand J Gastroenterol. 2019 Feb 8:1-10. doi: 10.1080/00365521.2019.1569124.
    PubMed     Abstract available


  104. KJAER MD, Qvist N, Nordgaard-Lassen I, Christensen LA, et al
    Adalimumab in the treatment of chronic pouchitis. A randomized double-blind, placebo-controlled trial.
    Scand J Gastroenterol. 2019;54:188-193.
    PubMed     Abstract available


    January 2019
  105. EVERHOV AH, Sachs MC, Malmborg P, Nordenvall C, et al
    Changes in inflammatory bowel disease subtype during follow-up and over time in 44,302 patients.
    Scand J Gastroenterol. 2019 Jan 31:1-9. doi: 10.1080/00365521.2018.1564361.
    PubMed     Abstract available


  106. MOHAN LJ, Daly JS, Ryan BM, Ramtoola Z, et al
    The future of nanomedicine in optimising the treatment of inflammatory bowel disease.
    Scand J Gastroenterol. 2019 Jan 24:1-9. doi: 10.1080/00365521.2018.1563805.
    PubMed     Abstract available


  107. BUER LCT, Moum BA, Cvancarova M, Warren DJ, et al
    Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort.
    Scand J Gastroenterol. 2019 Jan 16:1-8. doi: 10.1080/00365521.2018.1548646.
    PubMed     Abstract available


  108. VESTERGAARD T, Jorgensen SMD, Christensen LA, Julsgaard M, et al
    Pregnancy outcome in four women with inflammatory bowel disease treated with budesonide MMX.
    Scand J Gastroenterol. 2019 Jan 6:1-4. doi: 10.1080/00365521.2018.1533583.
    PubMed     Abstract available


  109. MOLANDER P, Jussila A, Toivonen T, Makkeli P, et al
    The impacts of an inflammatory bowel disease nurse specialist on the quality of care and costs in Finland.
    Scand J Gastroenterol. 2019 Jan 2:1-6. doi: 10.1080/00365521.2018.1541477.
    PubMed     Abstract available


  110. CHOUKOUR M, Kivits J, Baker A, Baumann C, et al
    Personalised medicine in inflammatory bowel diseases: a patient survey.
    Scand J Gastroenterol. 2019;54:135.
    PubMed    


  111. MONTEIRO S, Dias de Castro F, Leite S, Moreira MJ, et al
    Low fecal calprotectin predicts clinical remission in Crohn's disease patients: the simple answer to a challenging question.
    Scand J Gastroenterol. 2019;54:49-54.
    PubMed     Abstract available


    December 2018
  112. PROUDFOOT H, Norton C, Artom M, Didymus E, et al
    Targets for interventions for faecal incontinence in inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2018;53:1476-1483.
    PubMed     Abstract available


    November 2018
  113. KALLA R, Boyapati R, Vatn S, Hijos G, et al
    Patients' perceptions of faecal calprotectin testing in inflammatory bowel disease: results from a prospective multicentre patient-based survey.
    Scand J Gastroenterol. 2018 Nov 18:1-6. doi: 10.1080/00365521.2018.1527394.
    PubMed     Abstract available


    October 2018
  114. TRONSTAD RR, Polushina T, Brattbakk HR, Stansberg C, et al
    Genetic and transcriptional analysis of inflammatory bowel disease-associated pathways in patients with GUCY2C-linked familial diarrhea.
    Scand J Gastroenterol. 2018 Oct 24:1-10. doi: 10.1080/00365521.2018.1521867.
    PubMed     Abstract available


  115. NISHIO M, Ishii Y, Hashimoto Y, Otake H, et al
    Short- and long-term efficacy of adalimumab salvage therapy after failure of calcineurin inhibitors in steroid-refractory ulcerative colitis.
    Scand J Gastroenterol. 2018 Oct 24:1-9. doi: 10.1080/00365521.2018.1511825.
    PubMed     Abstract available


  116. OSSUM AM, Palm O, Cvancarova M, Solberg IC, et al
    Peripheral arthritis in patients with long-term inflammatory bowel disease. Results from 20 years of follow-up in the IBSEN study.
    Scand J Gastroenterol. 2018 Oct 24:1-7. doi: 10.1080/00365521.2018.1518482.
    PubMed     Abstract available


  117. RUNDQUIST S, Eriksson C, Nilsson L, Angelison L, et al
    Clinical effectiveness of golimumab in Crohn's disease: an observational study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2018 Oct 24:1-7. doi: 10.1080/00365521.2018.1519597.
    PubMed     Abstract available


  118. LEE JM, Kim YJ, Lee KM, Yoon H, et al
    Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 23:0-6. doi: 10.1080/00365521.2018.1524024.
    PubMed     Abstract available


  119. BAGER P, Vestergaard C, Juul T, Dahlerup JF, et al
    Population-based normative data for the inflammatory bowel disease fatigue scale - IBD-F.
    Scand J Gastroenterol. 2018 Oct 23:1-6. doi: 10.1080/00365521.2018.1521868.
    PubMed     Abstract available


  120. O'MORAIN N, O'Gorman S, McNamara D, Ryan B, et al
    Patients' attitudes toward treatment withdrawal in inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 9:1. doi: 10.1080/00365521.2018.1511827.
    PubMed    


  121. KATARINA PL, Sussanne B, Gunilla HF, Henrik H, et al
    The quality of care questionnaire: development of a valid measure for persons with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Oct 9:1-8. doi: 10.1080/00365521.2018.1495759.
    PubMed     Abstract available


    September 2018
  122. STEIN J, Walper A, Klemm W, Farrag K, et al
    Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice.
    Scand J Gastroenterol. 2018 Sep 17:1-7. doi: 10.1080/00365521.2018.1498914.
    PubMed     Abstract available


  123. LIRHUS SS, Hoivik ML, Moum B, Melberg HO, et al
    Regional differences in anti-TNF-alpha therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study.
    Scand J Gastroenterol. 2018 Sep 12:1-6. doi: 10.1080/00365521.2018.1495258.
    PubMed     Abstract available


  124. HUGUET JM, Iborra M, Bosca-Watts MM, Maroto N, et al
    Inflammatory bowel disease in patients over the age of 70 y. Does the disease duration influence its behavior?
    Scand J Gastroenterol. 2018 Sep 6:1-6. doi: 10.1080/00365521.2018.1501603.
    PubMed     Abstract available


  125. HAAPAMAKI J, Heikkinen E, Sipponen T, Roine RP, et al
    The impact of an adaptation course on health-related quality of life and functional capacity of patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Sep 2:1-5. doi: 10.1080/00365521.2018.1500639.
    PubMed     Abstract available


  126. JUDIT BERES N, Kiss Z, Muller KE, Cseh A, et al
    Role of microRNA-223 in the regulation of poly(ADP-ribose) polymerase in pediatric patients with Crohn's disease.
    Scand J Gastroenterol. 2018;53:1066-1073.
    PubMed     Abstract available


  127. SEGAL JP, Penez L, Mohsen Elkady S, Worley GHT, et al
    Long term outcomes of initial infliximab therapy for inflammatory pouch pathology: a multi-Centre retrospective study.
    Scand J Gastroenterol. 2018;53:1051-1058.
    PubMed     Abstract available


  128. VERSTOCKT B, Vermeire S, Van Assche G, Ferrante M, et al
    When IBD is not IBD.
    Scand J Gastroenterol. 2018;53:1085-1088.
    PubMed     Abstract available


  129. LI H, Gong Y, Xie Y, Sun Q, et al
    Clostridium butyricum protects the epithelial barrier by maintaining tight junction protein expression and regulating microflora in a murine model of dextran sodium sulfate-induced colitis.
    Scand J Gastroenterol. 2018;53:1031-1042.
    PubMed     Abstract available


    August 2018
  130. BUHL S, Kristina Borghede M, Brynskov J, Steenholdt C, et al
    Outcome of continued infliximab therapy in Crohn's disease patients with response but without remission after one year of infliximab - a retrospective cohort study.
    Scand J Gastroenterol. 2018;53:930-937.
    PubMed     Abstract available


  131. HOLLERAN G, Valerii G, Tortora A, Scaldaferri F, et al
    The use of single balloon enteroscopy in Crohn's disease and its impact on clinical outcome.
    Scand J Gastroenterol. 2018;53:925-929.
    PubMed     Abstract available


    July 2018
  132. VITIKAINEN K, Haapamaki J, Farkkila M, Anttila VJ, et al
    Clostridium difficile infection in patients with inflammatory bowel disease: a case control study.
    Scand J Gastroenterol. 2018 Jul 25:1-5. doi: 10.1080/00365521.2018.1492012.
    PubMed     Abstract available


  133. DROBNE D, Kurent T, Golob S, Svegl P, et al
    Success and safety of high infliximab trough levels in inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Jul 10:1-7. doi: 10.1080/00365521.2018.1486882.
    PubMed     Abstract available


  134. RIBALDONE DG, Vernero M, Astegiano M, Pellicano R, et al
    How ameliorate the adherence in patients with inflammatory bowel disease?
    Scand J Gastroenterol. 2018 Jul 3:1-2. doi: 10.1080/00365521.2018.1485731.
    PubMed    


  135. CARLSEN K, Riis LB, Elsberg H, Maagaard L, et al
    The sensitivity of fecal calprotectin in predicting deep remission in ulcerative colitis.
    Scand J Gastroenterol. 2018 Jul 3:1-6. doi: 10.1080/00365521.2018.1482956.
    PubMed     Abstract available


    June 2018
  136. XIE D, Zhang Y, Qu H
    Crucial genes of inflammatory bowel diseases explored by gene expression profiling analysis.
    Scand J Gastroenterol. 2018;53:685-691.
    PubMed     Abstract available


  137. HOIVIK ML, Buer LCT, Cvancarova M, Warren DJ, et al
    Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population.
    Scand J Gastroenterol. 2018;53:692-699.
    PubMed     Abstract available


  138. YAKYMENKO O, Schoultz I, Gullberg E, Strom M, et al
    Infliximab restores colonic barrier to adherent-invasive E. coli in Crohn's disease via effects on epithelial lipid rafts.
    Scand J Gastroenterol. 2018;53:677-684.
    PubMed     Abstract available


  139. SEGAL JP, Chan H, Collins B, Faiz OD, et al
    Biofeedback in patients with ileoanal pouch dysfunction: a specialist centre experience.
    Scand J Gastroenterol. 2018;53:665-669.
    PubMed     Abstract available


  140. SCHULZE H, Esters P, Hartmann F, Stein J, et al
    A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients.
    Scand J Gastroenterol. 2018;53:670-676.
    PubMed     Abstract available


    May 2018
  141. YADAV A, Foromera J, Falchuk KR, Feuerstein JD, et al
    Biologics and immunomodulators for treating Crohn's disease developing after surgery for an initial diagnosis of ulcerative colitis: a review of current literature.
    Scand J Gastroenterol. 2018 May 2:1-5. doi: 10.1080/00365521.2018.1468478.
    PubMed     Abstract available


    April 2018
  142. YERUSHALMY-FELER A, Ben-Tov A, Weintraub Y, Amir A, et al
    High and low body mass index may predict severe disease course in children with inflammatory bowel disease.
    Scand J Gastroenterol. 2018 Apr 24:1-6. doi: 10.1080/00365521.2018.1464595.
    PubMed     Abstract available


  143. RATNAKUMARAN R, To N, Gracie DJ, Selinger CP, et al
    Efficacy and tolerability of initiating, or switching to, infliximab biosimilar CT-P13 in inflammatory bowel disease (IBD): a large single-centre experience.
    Scand J Gastroenterol. 2018 Apr 24:1-8. doi: 10.1080/00365521.2018.1464203.
    PubMed     Abstract available


  144. KANG EA, Yoon H, Seo AY, Shin CM, et al
    Characteristics of cytomegalovirus enterocolitis in patients with or without inflammatory bowel diseases.
    Scand J Gastroenterol. 2018;53:453-458.
    PubMed     Abstract available


  145. SONG EM, Kim N, Lee SH, Chang K, et al
    Clinical characteristics and long-term prognosis of elderly-onset Crohn's disease.
    Scand J Gastroenterol. 2018;53:417-425.
    PubMed     Abstract available


  146. XAVIER S, Curdia Goncalves T, Dias de Castro F, Magalhaes J, et al
    Perianal Crohn's disease - association with significant inflammatory activity in proximal small bowel segments.
    Scand J Gastroenterol. 2018;53:426-429.
    PubMed     Abstract available


    March 2018
  147. KEIL R, Wasserbauer M, Zadorova Z, Kojecky V, et al
    Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
    Scand J Gastroenterol. 2018 Mar 21:1-7. doi: 10.1080/00365521.2018.1451915.
    PubMed     Abstract available


  148. WICKBOM A, Bohr J, Nyhlin N, Eriksson A, et al
    Microscopic colitis in patients with ulcerative colitis or Crohn's disease: a retrospective observational study and review of the literature.
    Scand J Gastroenterol. 2018 Mar 16:1-7. doi: 10.1080/00365521.2018.1430252.
    PubMed     Abstract available


  149. AHLUWALIA B, Moraes L, Magnusson MK, Ohman L, et al
    Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies.
    Scand J Gastroenterol. 2018 Mar 9:1-11. doi: 10.1080/00365521.2018.1447597.
    PubMed     Abstract available


  150. DIGNASS A, Akbar A, Baumgart DC, Bommelaer G, et al
    Granulocyte/monocyte adsorptive apheresis for the treatment of therapy-refractory chronic active ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447598.
    PubMed     Abstract available


  151. ZAGOROWICZ E, Przybysz A, Szlak J, Magdziak A, et al
    Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis.
    Scand J Gastroenterol. 2018 Mar 7:1-7. doi: 10.1080/00365521.2018.1447596.
    PubMed     Abstract available


  152. AALTONEN G, Ristimaki A, Keranen I, Carpelan-Holmstrom M, et al
    Does a histologically inflamed resection margin increase postoperative complications in patients with Crohn's disease?
    Scand J Gastroenterol. 2018;53:279-283.
    PubMed     Abstract available


    February 2018
  153. KANGASPUNTA M, Haapamaki J, Farkkila M, Arkkila P, et al
    Inflammatory bowel disease and anemia: intravenous iron treatment.
    Scand J Gastroenterol. 2018 Feb 22:1-5. doi: 10.1080/00365521.2018.1441435.
    PubMed     Abstract available


  154. GREENSTEIN RJ, Brown ST
    A data-based hypothesis explicating the observations that "Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study".
    Scand J Gastroenterol. 2018 Feb 15:1. doi: 10.1080/00365521.2018.1440003.
    PubMed    


  155. HAKIMIAN S, Kheder J, Arum S, Cave DR, et al
    Re-evaluating osteoporosis and fracture risk in Crohn's disease patients in the era of TNF-alpha inhibitors.
    Scand J Gastroenterol. 2018;53:168-172.
    PubMed     Abstract available


    January 2018
  156. MOORE C
    Response to "Clinical implications of assay-specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time".
    Scand J Gastroenterol. 2018 Jan 31:1. doi: 10.1080/00365521.2018.1428400.
    PubMed    


  157. KLEPP P, Kisiel JB, Smastuen MC, Roseth A, et al
    Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study.
    Scand J Gastroenterol. 2018 Jan 9:1-6. doi: 10.1080/00365521.2018.1424935.
    PubMed     Abstract available


  158. LINDSTROM L, Jorgensen KK, Boberg KM, Castedal M, et al
    Risk factors and prognosis for recurrent primary sclerosing cholangitis after liver transplantation: a Nordic Multicentre Study.
    Scand J Gastroenterol. 2018 Jan 4:1-8. doi: 10.1080/00365521.2017.1421705.
    PubMed     Abstract available


  159. SUNDE ML, Ricanek P, Oresland T, Jahnsen J, et al
    Determinants of optimal bowel function in ileal pouch-anal anastomosis - physiological differences contributing to pouch function.
    Scand J Gastroenterol. 2018;53:8-14.
    PubMed     Abstract available


  160. PALATKA K, Kacska S, Lovas S, Garai I, et al
    The potential role of FDG PET-CT in the characterization of the activity of Crohn's disease, staging follow-up and prognosis estimation: a pilot study.
    Scand J Gastroenterol. 2018;53:24-30.
    PubMed     Abstract available


    December 2017
  161. SALIH A, Widbom L, Hultdin J, Karling P, et al
    Smoking is associated with risk for developing inflammatory bowel disease including late onset ulcerative colitis: a prospective study.
    Scand J Gastroenterol. 2017 Dec 21:1-6. doi: 10.1080/00365521.2017.1418904.
    PubMed     Abstract available


  162. YLISAUKKO-OJA T, Aaltonen J, Nuutinen H, Blomster T, et al
    High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)().
    Scand J Gastroenterol. 2017 Dec 19:1-10. doi: 10.1080/00365521.2017.1416160.
    PubMed     Abstract available


  163. RIBALDONE DG, Vernero M, Saracco GM, Pellicano R, et al
    The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets.
    Scand J Gastroenterol. 2017 Dec 11:1-6. doi: 10.1080/00365521.2017.1405070.
    PubMed     Abstract available


  164. LIMKETKAI BN, Sepulveda R, Hing T, Shah ND, et al
    Prevalence and factors associated with gluten sensitivity in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Dec 7:1-5. doi: 10.1080/00365521.2017.1409364.
    PubMed     Abstract available


    November 2017
  165. GARCIA-PLANELLA E, Manosa M, Chaparro M, Beltran B, et al
    Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
    Scand J Gastroenterol. 2017 Nov 30:1-6. doi: 10.1080/00365521.2017.1410219.
    PubMed     Abstract available


  166. NISHIDA Y, Hosomi S, Watanabe K, Watanabe K, et al
    Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis.
    Scand J Gastroenterol. 2017 Nov 24:1-7. doi: 10.1080/00365521.2017.1403647.
    PubMed     Abstract available


  167. KOMPEROD MJ, Sommer C, Mellin-Olsen T, Iversen PO, et al
    Persistent symptoms in patients with Crohn's disease in remission: An exploratory study on the role of diet.
    Scand J Gastroenterol. 2017 Nov 23:1-6. doi: 10.1080/00365521.2017.1397736.
    PubMed     Abstract available


  168. BAGER P, Chauhan U, Greveson K, Jaghult S, et al
    Systematic review: advice lines for patients with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Nov 13:1-7. doi: 10.1080/00365521.2017.1401116.
    PubMed     Abstract available


    October 2017
  169. THEOCHARI NA, Stefanopoulos A, Mylonas KS, Economopoulos KP, et al
    Antibiotics exposure and risk of inflammatory bowel disease: a systematic review.
    Scand J Gastroenterol. 2017 Oct 12:1-7. doi: 10.1080/00365521.2017.1386711.
    PubMed     Abstract available



  170. Correction to: Carvalho et al., Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017;52:ii.
    PubMed    


    September 2017
  171. KRIDIN K, Zelber-Sagi S, Comaneshter D, Cohen AD, et al
    Ulcerative colitis associated with pemphigus: a population-based large-scale study.
    Scand J Gastroenterol. 2017 Sep 28:1-5. doi: 10.1080/00365521.2017.1380839.
    PubMed     Abstract available


    August 2017
  172. EBERL A, Huoponen S, Pahikkala T, Blom M, et al
    Switching maintenance infliximab therapy to biosimilar infliximab in inflammatory bowel disease patients.
    Scand J Gastroenterol. 2017 Aug 24:1-6. doi: 10.1080/00365521.2017.1369561.
    PubMed     Abstract available


  173. SAFFOURI G, Gupta A, Loftus EV Jr, Baddour LM, et al
    The incidence and outcomes from Clostridium difficile infection in hospitalized adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Aug 6:1-8. doi: 10.1080/00365521.2017.1362466.
    PubMed     Abstract available


    July 2017
  174. KHAJAH MA
    The potential role of fecal microbiota transplantation in the treatment of inflammatory Bowel disease.
    Scand J Gastroenterol. 2017 Jul 7:1-13. doi: 10.1080/00365521.2017.1347812.
    PubMed     Abstract available


    June 2017
  175. SMIDS C, Horjus Talabur Horje CS, Groenen MJM, van Koolwijk EHM, et al
    The value of serum antibodies in differentiating inflammatory bowel disease, predicting disease activity and disease course in the newly diagnosed patient.
    Scand J Gastroenterol. 2017 Jun 29:1-9. doi: 10.1080/00365521.2017.1344875.
    PubMed     Abstract available


  176. CARVALHO FSG, de Medeiros IA, Antunes H
    Prevalence of iron deficiency anemia and iron deficiency in a pediatric population with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jun 23:1-5. doi: 10.1080/00365521.2017.1342137.
    PubMed     Abstract available



  177. Correction to: Kokkinidis DG, et al. Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 Jun 23:1. doi: 10.1080/00365521.2017.1341083.
    PubMed    


  178. ABOLFOTOUH S, Rautio T, Klintrup K, Helavirta I, et al
    Predictors of quality-of-life after ileal pouch-anal anastomosis in patients with ulcerative colitis.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1337218.
    PubMed     Abstract available


  179. CON D, Jackson B, Gray K, De Cruz P, et al
    eHealth for inflammatory bowel disease self-management - the patient perspective.
    Scand J Gastroenterol. 2017 Jun 9:1-8. doi: 10.1080/00365521.2017.1333625.
    PubMed     Abstract available


  180. ROTHSCHILD B, Rinawi F, Herman Y, Nir O, et al
    Prognostic significance of granulomas in children with Crohn's disease.
    Scand J Gastroenterol. 2017;52.
    PubMed     Abstract available


  181. CARDILE S, Alterio T, Candusso M, Pietrobattista A, et al
    Autoimmune liver diseases and inflammatory bowel diseases in children: current issues and future perspectives.
    Scand J Gastroenterol. 2017;52.
    PubMed     Abstract available


    May 2017
  182. MACALUSO FS, Renna S, Maida M, Dimarco M, et al
    Tolerability profile of thiopurines in inflammatory bowel disease: a prospective experience.
    Scand J Gastroenterol. 2017 May 29:1-7. doi: 10.1080/00365521.2017.1333626.
    PubMed     Abstract available


  183. JACKSON B, Con D, Ma R, Gorelik A, et al
    Health care costs associated with Australian tertiary inflammatory bowel disease care.
    Scand J Gastroenterol. 2017 May 16:1-6. doi: 10.1080/00365521.2017.1323117.
    PubMed     Abstract available


  184. KOKKINIDIS DG, Bosdelekidou EE, Iliopoulou SM, Tassos AG, et al
    Emerging treatments for ulcerative colitis: a systematic review.
    Scand J Gastroenterol. 2017 May 14:1-9. doi: 10.1080/00365521.2017.1326163.
    PubMed     Abstract available


  185. SEO H, Chang K, Lee SH, Song EM, et al
    Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
    Scand J Gastroenterol. 2017 May 14:1-7. doi: 10.1080/00365521.2017.1323229.
    PubMed     Abstract available


  186. MARTELLI L, Colard A, Fontaine F, Deflandre J, et al
    Evaluation of the efficacy of octreotide LAR in the treatment of Crohn's disease associated refractory diarrhea.
    Scand J Gastroenterol. 2017;52:564-569.
    PubMed     Abstract available


  187. SASIDHARAN S, Yajnik V, Khalili H, Garber J, et al
    Genetic risk factors for serious infections in inflammatory bowel diseases.
    Scand J Gastroenterol. 2017;52:570-576.
    PubMed     Abstract available


  188. VARMA P, Falconer J, Aga A, Prince HM, et al
    Rituximab-induced Crohn's disease.
    Scand J Gastroenterol. 2017;52:606-608.
    PubMed     Abstract available


  189. RINAWI F, Assa A, Eliakim R, Mozer-Glassberg Y, et al
    The natural history of pediatric-onset IBD-unclassified and prediction of Crohn's disease reclassification: a 27-year study.
    Scand J Gastroenterol. 2017;52:558-563.
    PubMed     Abstract available


  190. RYSKA O, Serclova Z, Mestak O, Matouskova E, et al
    Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn's disease.
    Scand J Gastroenterol. 2017;52:543-550.
    PubMed     Abstract available


    April 2017
  191. KWAPISZ L, Gregor J, Chande N, Yan B, et al
    The utility of fecal calprotectin in predicting the need for escalation of therapy in inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 20:1-5. doi: 10.1080/00365521.2017.1315740.
    PubMed     Abstract available


  192. LEE KE, Jung SA, Yoon H, Park SH, et al
    Factors associated with pregnancy-related knowledge in women of reproductive age with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Apr 7:1-7. doi: 10.1080/00365521.2017.1310288.
    PubMed     Abstract available


    March 2017
  193. JAIME F, Riutort MC, Alvarez-Lobos M, Hoyos-Bachiloglu R, et al
    Solar radiation is inversely associated with inflammatory bowel disease admissions.
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1307444.
    PubMed     Abstract available


  194. ERIKSSON C, Marsal J, Bergemalm D, Vigren L, et al
    Long-term effectiveness of vedolizumab in inflammatory bowel disease: a national study based on the Swedish National Quality Registry for Inflammatory Bowel Disease (SWIBREG).
    Scand J Gastroenterol. 2017 Mar 31:1-8. doi: 10.1080/00365521.2017.1304987.
    PubMed     Abstract available


  195. WLODARCZYK M, Sobolewska-Wlodarczyk A, Cygankiewicz AI, Jacenik D, et al
    G protein-coupled receptor 55 (GPR55) expresses differently in patients with Crohn's disease and ulcerative colitis.
    Scand J Gastroenterol. 2017 Mar 8:1-5. doi: 10.1080/00365521.2017.1298834.
    PubMed     Abstract available


  196. MURRAY IA, Murray LK, Woolson KL, Sherfi H, et al
    Incidence and predictive factors for positive 75SeHCAT test: improving the diagnosis of bile acid diarrhoea.
    Scand J Gastroenterol. 2017 Mar 5:1-6. doi: 10.1080/00365521.2017.1298153.
    PubMed     Abstract available


  197. MARTI-GALLOSTRA M, Myrelid P, Mortensen N, Keshav S, et al
    The role of a defunctioning stoma for colonic and perianal Crohn's disease in the biological era.
    Scand J Gastroenterol. 2017;52:251-256.
    PubMed     Abstract available


  198. BAR-GIL SHITRIT A, Koslowsky B, Livovsky DM, Shitrit D, et al
    A prospective study of fecal calprotectin and lactoferrin as predictors of small bowel Crohn's disease in patients undergoing capsule endoscopy.
    Scand J Gastroenterol. 2017;52:328-333.
    PubMed     Abstract available


    February 2017
  199. WALDUM HL, Bjornsson ES, Brenna E
    Chronic cholestatic liver diseases.
    Scand J Gastroenterol. 2017 Feb 28:1. doi: 10.1080/00365521.2017.1296276.
    PubMed    


  200. BOND A, Dodd S, Fisher G, Skouras T, et al
    Concurrent immunomodulator therapy is associated with higher adalimumab trough levels during scheduled maintenance therapy.
    Scand J Gastroenterol. 2017;52:204-208.
    PubMed     Abstract available


    January 2017
  201. YE X, Liu S, Hu M, Song Y, et al
    CCR5 expression in inflammatory bowel disease and its correlation with inflammatory cells and beta-arrestin2 expression.
    Scand J Gastroenterol. 2017 Jan 31:1-10. doi: 10.1080/00365521.2017.1281435.
    PubMed     Abstract available


  202. JACKSON BD, Con D, Liew D, De Cruz P, et al
    Clinicians' adherence to international guidelines in the clinical care of adults with inflammatory bowel disease.
    Scand J Gastroenterol. 2017 Jan 27:1-7. doi: 10.1080/00365521.2017.1278785.
    PubMed     Abstract available


  203. LANDERHOLM K, Abdalla M, Myrelid P, Andersson RE, et al
    Survival of ileal pouch anal anastomosis constructed after colectomy or secondary to a previous ileorectal anastomosis in ulcerative colitis patients: a population-based cohort study.
    Scand J Gastroenterol. 2017 Jan 19:1-5. doi: 10.1080/00365521.2016.1278457.
    PubMed     Abstract available


  204. RONNBLOM A, Holmstrom T, Karlbom U, Tanghoj H, et al
    Clinical course of Crohn's disease during the first 5 years. Results from a population-based cohort in Sweden (ICURE) diagnosed 2005-2009.
    Scand J Gastroenterol. 2017;52:81-86.
    PubMed     Abstract available


  205. VALERIO DE AZEVEDO S, Maltez C, Lopes AI
    Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Scand J Gastroenterol. 2017;52:29-33.
    PubMed     Abstract available


  206. BEAUPEL N, Brouquet A, Abdalla S, Carbonnel F, et al
    Preoperative oral polymeric diet enriched with transforming growth factor-beta 2 (Modulen) could decrease postoperative morbidity after surgery for complicated ileocolonic Crohn's disease.
    Scand J Gastroenterol. 2017;52:5-10.
    PubMed     Abstract available


    December 2016
  207. GRIMSTAD T, Skoie IM, Doerner J, Isaksen K, et al
    TWEAK is not elevated in patients with newly diagnosed inflammatory bowel disease.
    Scand J Gastroenterol. 2016 Dec 31:1-5. doi: 10.1080/00365521.2016.1273382.
    PubMed     Abstract available


  208. CANCADO GG, Vilela EG
    Guillain-Barre syndrome during adalimumab therapy for Crohn s disease: coincidence or consequence?
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  209. LAURELL A, Sjoberg K
    Prebiotics and synbiotics in ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  210. BROMS G, Granath F, Stephansson O, Kieler H, et al
    Preterm birth in women with inflammatory bowel disease - the association with disease activity and drug treatment.
    Scand J Gastroenterol. 2016;51:1462-1469.
    PubMed     Abstract available


    November 2016
  211. OLBJORN C, Cvancarova Smastuen M, Thiis-Evensen E, Nakstad B, et al
    Serological markers in diagnosis of pediatric inflammatory bowel disease and as predictors for early tumor necrosis factor blocker therapy.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  212. AMCOFF K, Stridsberg M, Lampinen M, Magnuson A, et al
    Clinical implications of assay specific differences in f-calprotectin when monitoring inflammatory bowel disease activity over time.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  213. LANKARANI KB, Sepehrimanesh M, Seghatoleslami F, Hoseini SE, et al
    Autophagy-related protein 7 level in patients with ulcerative colitis.
    Scand J Gastroenterol. 2016.
    PubMed    


  214. ZHOU G, Yang W, Yu L, Yu T, et al
    CD99 refers to the activity of inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  215. HUPPERTZ-HAUSS G, Hoivik ML, Jelsness-Jorgensen LP, Opheim R, et al
    Fatigue in a population-based cohort of patients with inflammatory bowel disease 20 years after diagnosis: The IBSEN study.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  216. ENGLUND H, Liden K K, Lind T, Sundstrom T, et al
    Radiation exposure in patients with inflammatory bowel disease and irritable bowel syndrome in the years 2001-2011.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  217. MOLANDER P, Farkkila M, Kemppainen H, Blomster T, et al
    Long-term outcome of inflammatory bowel disease patients with deep remission after discontinuation of TNFalpha-blocking agents.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    October 2016
  218. JAKOBSSON GL, Sternegard E, Olen O, Myrelid P, et al
    Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG).
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    September 2016
  219. HOGBERG C, Karling P, Rutegard J, Lilja M, et al
    Diagnosing colorectal cancer and inflammatory bowel disease in primary care: The usefulness of tests for faecal haemoglobin, faecal calprotectin, anaemia and iron deficiency. A prospective study.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  220. MUTHAS D, Reznichenko A, Balendran CA, Bottcher G, et al
    Neutrophils in Ulcerative Colitis: A review of selected biomarkers and their potential therapeutic implications.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    August 2016
  221. LEHTOLA E, Haapamaki J, Farkkila MA
    Outcome of inflammatory bowel disease patients treated with TNF-alpha inhibitors: two-year follow-up.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  222. KISZKA-KANOWITZ M, Theede K, Mertz-Nielsen A
    Randomized clinical trial: a pilot study comparing efficacy of low-dose azathioprine and allopurinol to azathioprine on clinical outcomes in inflammatory bowel disease.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  223. PROSBERG M, Bendtsen F, Vind I, Petersen AM, et al
    The association between the gut microbiota and the inflammatory bowel disease activity: a systematic review and meta-analysis.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    July 2016
  224. HOLT DQ, Strauss BJ, Lau KK, Moore GT, et al
    Body composition analysis using abdominal scans from routine clinical care in patients with Crohn's Disease.
    Scand J Gastroenterol. 2016;51:842-7.
    PubMed     Abstract available


    June 2016
  225. VON VOLKMANN HL, Nylund K, Tronstad RR, Hovdenak N, et al
    An activating gucy2c mutation causes impaired contractility and fluid stagnation in the small bowel.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


    January 2016
  226. MOUSSATA D, Boschetti G, Stefanescu C, Nancey S, et al
    Isolated ileitis associated with primary sclerosing cholangitis in three patients with Crohn's disease.
    Scand J Gastroenterol. 2016.
    PubMed     Abstract available


  227. FERREIRO-IGLESIAS R, Barreiro-de Acosta M, Lorenzo-Gonzalez A, Dominguez-Munoz JE, et al
    Usefulness of a rapid faecal calprotectin test to predict relapse in Crohn's disease patients on maintenance treatment with adalimumab.
    Scand J Gastroenterol. 2016;51:442-7.
    PubMed     Abstract available


  228. PARK SK, Hong M, Ye BD, Kim KJ, et al
    Influences of XDH genotype by gene-gene interactions with SUCLA2 for thiopurine-induced leukopenia in Korean patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:684-91.
    PubMed     Abstract available


  229. DIGE A, Magnusson MK, Ohman L, Hvas CL, et al
    Reduced numbers of mucosal DR(int) macrophages and increased numbers of CD103(+) dendritic cells during anti-TNF-alpha treatment in patients with Crohn's disease.
    Scand J Gastroenterol. 2016;51:692-9.
    PubMed     Abstract available


  230. GABRYEL M, Skrzypczak-Zielinska M, Kucharski MA, Slomski R, et al
    The impact of genetic factors on response to glucocorticoids therapy in IBD.
    Scand J Gastroenterol. 2016;51:654-65.
    PubMed     Abstract available


  231. HERRANZ BACHILLER MT, Barrio Andres J, Fernandez Salazar L, Ruiz-Zorrilla R, et al
    The utility of faecal calprotectin to predict post-operative recurrence in Crohns disease.
    Scand J Gastroenterol. 2016;51:720-6.
    PubMed     Abstract available


  232. COELHO R, Magro F, Silva M, Macedo G, et al
    Early surgery in Crohn's disease patients with entero-urinary fistulas: does it change the prognosis?
    Scand J Gastroenterol. 2016;51:679-83.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: